Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind dose-ranging study of conbercept versus Eylea in treatment-naive neovascular age-related macular degeneration
MOH_2018-11-25_003706Phase 3Not yet recruiting
- Sponsor
- Chengdu Kanghong Biotechnology Co., Ltd.
- Start
- Nov 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of conbercept and aflibercept in exudative macular degeneration (3 arms), sponsored by Chengdu Kanghong Biotechnology Co., Ltd. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
conberceptaflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on MOH_2018-11-25_003706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-11-25_003706.